GREENFIELD, Ind., June 11, 2018 /PRNewswire/ -- Elanco Animal
Health, a division of Eli Lilly and Company (NYSE: LLY), today
announces licensing of Prevacent® PRRS by
the USDA, a modified-live respiratory vaccine that has been shown
to be effective in the reduction of porcine reproductive and
respiratory syndrome (PRRS), respiratory form, in piglets two weeks
or older.
PRRS means fewer pigs, higher costs
Since
its emergence in the late 1980s, PRRS has cost the swine industry
millions annually in respiratory disease in piglets and
reproductive failure in sows.
"PRRS has grown to be a costly and challenging disease that is
difficult to control at the local, regional and national levels,"
says Chris Chavis, senior director,
Elanco North America Food Animal Business. "We are eager to bring
producers a new product to tackle this devastating disease."
Currently, it is estimated that PRRS costs the swine industry
$560 to $660
million annually, with the breeding herd costs accounting
for 45 percent of the total industry cost. 1
Long-lasting immunity
"Elanco is excited
to be able to provide producers and the entire swine industry with
a new product that is proven effective against the respiratory form
of PRRS," says Chavis. "Not only is it safe to use in piglets two
weeks or older, Prevacent PRRS has a demonstrated duration of
immunity of 26 weeks for the respiratory form of PRRS."
The viral strain in Prevacent PRRS is highly relevant to today's
swine operations so producers can be confident that they are
getting effective protection against the respiratory form of PRRS
for their piglets.
Cross-protection studies
"The contemporary
strain in Prevacent PRRS demonstrated cross protection against
multiple difficult viral strains that may pose a threat to swine
operations. Prevacent PRRS is a timely and effective solution for
to meet the PRRS challenges producers are facing today," says
Chavis.
Prevacent PRRS is a key part of Elanco's Full Value
Pigs®, which includes a complete portfolio
of products that help to control specific enteric and respiratory
diseases.
About Elanco
Elanco provides comprehensive
products and knowledge services to improve animal health and
food-animal production in more than 70 countries around the world.
We value innovation, both in scientific research and daily
operations, and strive to cultivate a collaborative work
environment for more than 6,500 employees worldwide. Together with
our customers, we are committed to raising awareness about global
food security, and celebrating and supporting the human-animal
bond. Founded in 1954, Elanco is a division of Eli Lilly and
Company. Our worldwide headquarters and research facilities are
located in Greenfield, Indiana.
Visit us at Elanco.com and EnoughMovement.com.
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about Prevacent PRRS as a treatment for porcine reproductive
and respiratory syndrome and reflect Elanco's current belief. As
with any vaccine products, however, there are substantial risks and
uncertainties in the process of development and commercialization.
Among other things, there can be no guarantee that future study
results will be consistent with the results to date or that the
product will be commercially successful. For further discussion of
these and other risks and uncertainties, see Lilly's most recent
Form 10-K and Form 10-Q filings with the United States Securities
and Exchange Commission. Except as required by law, Elanco
undertakes no duty to update forward-looking statements to reflect
events after the date of this release.
1Neumann, E.J., et al. (2005). Assessment of the
economic impact of porcine reproductive and respiratory syndrome on
swine production in the United
States. Journal of the American Veterinary Medical
Association, 227(3), 385-392.
Prevacent, Full Value Pigs, Elanco, and the diagonal bar logo
are trademarks of Elanco or its affiliates.
© 2018 Elanco or its affiliates.
vaccin 10951-6 | USSBUPRE00005
View original
content:http://www.prnewswire.com/news-releases/elanco-animal-health-introduces-new-respiratory-prrs-vaccine-300662509.html
SOURCE Elanco